A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
Public ClinicalTrials.gov record NCT05143177. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Adaptive Phase 2/3 Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel, 2 Arm Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an adaptive Phase 2/3 multicenter, double-blind, placebo-controlled, randomized, parallel, 2 arm study to evaluate the efficacy and safety of DA-1229 compared to placebo in patients with calcific aortic valve disease with mild to moderate aortic stenosis. There are 2 arms in this study to which patients will be randomized in a ratio of 1:1 to receive the DA-1229 or placebo orally once daily for a period of 104 weeks. The 2 arms are: placebo and DA-1229 10 mg Group. The study will have three phases: Screening Period (up to 4 weeks), Treatment Period (104 weeks), and Follow-Up Period (2-4 weeks). Total Study Duration is112 Weeks.
Study identification
- NCT ID
- NCT05143177
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 486 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 35 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 27, 2022 (Actual)
- Primary completion
- Mar 21, 2026 (Actual)
- Completion
- Mar 26, 2026 (Actual)
- Last update posted
- Aug 18, 2026
2022 – 2026
United States locations
- U.S. sites
- 24
- U.S. states
- 17
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic, AZ | Phoenix | Arizona | 85054 | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Mayo Clinic, FL | Jacksonville | Florida | 32224 | — |
| Baycare Health systems | Safety Harbor | Florida | 34695 | — |
| Northside Hospital | Atlanta | Georgia | 30342 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Beaumont Hospital, Royal Oak | Royal Oak | Michigan | 48073 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Hackensack Meridian Health | Hackensack | New Jersey | 07601 | — |
| Rutgers- Robert Wood Johnson Medical School | New Brunswick | New Jersey | 08901 | — |
| Ichan School of Medicine | New York | New York | 10025 | — |
| Stony brook | Stony Brook | New York | 11974 | — |
| Christ Hospital | Cincinnati | Ohio | 45219 | — |
| OhioHealth Research Institute | Columbus | Ohio | 43214 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| University of Pittsburgh Medical Center | Mechanicsburg | Pennsylvania | 17050 | — |
| Einstein Medical Center Philadelphia | Philadelphia | Pennsylvania | 19141 | — |
| Texas Heart Institute | Houston | Texas | 77030 | — |
| The University of Vermont Medical Center | Burlington | Vermont | 05401 | — |
| Inova Health Care Services | Falls Church | Virginia | 22042 | — |
| Aurora Research Institute | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05143177, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 18, 2026 · Synced Nov 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05143177 live on ClinicalTrials.gov.